Orchard Therapeutics Plc's Customers Performance

Name: Orchard Therapeutics Plc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

ORTX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


ORTX's Source of Revenues		During the corresponding time, Orchard Therapeutics Plc recorded a revenue increase by 9.09 % year on year, sequentially revenue fell by -13.84 %. While revenue at the Orchard Therapeutics Plc's corporate clients • List of ORTX Customers

for the same period Orchard Therapeutics Plc recorded revenue increase by 9.09 % year on year, sequentially revenue fell by -13.84 %.

• List of ORTX Customers

Orchard Therapeutics Plc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Orchard Therapeutics Plc's Comment on Sales, Marketing and Customers

News about Orchard Therapeutics Plc Contracts

Revolutionary Gene Therapy for Early-onset Metachromatic Leukodystrophy Launches in the U.S., Offering Hope and Convenience for Affected Families

Orchard Therapeutics, a global gene therapy company, recently announced its plans for the U.S. launch of Lenmeldy (atidarsagene autotemcel), the first and only approved therapy for children with Early-onset Metachromatic Leukodystrophy (EO-MLD). This groundbreaking treatment aims to transform the lives of patients suffering from this rare and devastating genetic disorder.Metachromatic Leukodystrophy (MLD) is a rare inherited disorder characterized by the lack of a vital enzyme called arylsulfatase-A (ASA). As a result, toxic substances accumulate in the body, leading to the destruction of the protective coating around nerve cells in the brain and spinal cord, known as myelin. This loss of myelin results in t...

ORTX's Stock Performance relative to it's Customers

ORTX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Orchard Therapeutics Plc	381.41	21.84	-72.92	100
SUBTOTAL	0.00	0.00	0.00	-

Sources: Orchard Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Orchard Therapeutics Plc’s corporate clients.
For your research, we’ve provided 9 tables on Orchard Therapeutics Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.